Latest news with #PharmaIntelligenceCenter
Yahoo
3 days ago
- Business
- Yahoo
Myelodysplastic Syndrome Competitive Landscape 2025: 262 Molecules in MDS Pipeline - A Peek into Future Therapeutics
Discover the competitive landscape of Myelodysplastic Syndrome (MDS) therapeutics. With 498,757 cases in 2024 and a slight increase by 2029, the report reveals a robust pipeline of 262 molecules and over 1,200 clinical trials. Uncover key market players, future catalysts, and strategic insights for effective market positioning. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Myelodysplastic Syndrome: Competitive Landscape" report has been added to reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics. The analyst epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies. The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase III development, and 87 assets in Phase II. Over the past decade, 1,229 clinical trials have been conducted in MDS. During the past decade, partnerships were most prevalent in North America and Europe. Report ScopeThe Myelodysplastic Syndrome Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease of the report include: Disease Landscape Disease Overview Epidemiology Overview Treatment Overview Marketed Products Assessment Breakdown by Mechanism of Action, Route of Administration Product Profiles with Sales Forecast Pricing and Reimbursement Assessment Annual Therapy Cost Time to Pricing and Time to Reimbursement Pipeline Assessment Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration Product Profiles with Sales Forecast Late-to-mid-stage Pipeline Drugs Phase Transition Success Rate and Likelihood of Approval Clinical Trials Assessment Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status Enrolment Analytics, Site Analytics, Feasibility Analysis Deals Landscape Mergers, Acquisitions, and Strategic Alliances by Region Overview of Recent Deals Commercial Assessment Key Market Players Future Market Catalysts Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the Myelodysplastic Syndrome Therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Myelodysplastic Syndrome Therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered: 1 Preface2 Key Findings3 Disease Landscape3.1 Disease Overview3.2 Epidemiology Overview3.3 Treatment Overview4 Marketed Drugs Assessment4.1 Leading Marketed Drugs4.2 Overview by Mechanism of Action4.3 Overview by Molecule Type4.4 Product Profiles and Sales Forecast5 Pricing and Reimbursement Assessment5.1 Annual Cost of Therapy5.2 Time to Pricing and Reimbursement6 Pipeline Drugs Assessment6.1 Mid-to-late-stage Pipeline Drugs6.2 Overview by Development Stage6.3 Overview by Mechanism of Action6.4 Overview by Molecule Type6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)6.6 Therapy Area and Indication-specific PTSR and LoA7 Clinical Trials Assessment7.1 Historical Overview7.2 Overview by Phase7.3 Overview by Status7.4 Overview by Phase for Ongoing and Planned Trials7.5 Trials with Virtual Components7.6 Overview of Trials by Geography7.7 Single-Country and Multinational Trials by Region7.8 Top 20 Sponsors with Breakdown by Phase7.9 Top 20 Sponsors with Breakdown by Status7.10 Overview by Endpoint Status7.11 Overview by Race and Ethnicity7.12 Enrollment Data7.13 Top 20 countries for Trial Sites7.14 Top 20 Sites Globally7.15 Feasibility Analysis - Geographic Overview7.16 Feasibility Analysis - Benchmark Models8 Deals Landscape8.1 Mergers, Acquisitions, and Strategic Alliances by Region8.2 Recent Mergers, Acquisitions, and Strategic Alliances9 Commercial Assessment9.1 Key Market Players10 Future Market CatalystsFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
25-03-2025
- Health
- Yahoo
GSK and UK researchers plan to study Shingrix and dementia risk reduction link
GSK is collaborating with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to investigate whether GSK's shingles vaccine, Shingrix (zoster vaccine recombinant), could reduce the risk of dementia. The research plan follows multiple retrospective observational studies, which suggest a potential link between shingles vaccination – specifically with Shingrix – and a lower likelihood of developing dementia. However, given unmeasured confounding factors, GSK has cautioned that these studies cannot establish causation. The new study will analyse electronic health records from the UK's National Health Service (NHS), focusing on approximately 1.4 million individuals who are 65 or 66 years old. Researchers will assess how shingles vaccination affects dementia risk while accounting for variables such as age, sex, and existing medical conditions. The study is expected to take four years to complete. Interest in the potential cognitive benefits of Shingrix was highlighted by a 2024 study published in Nature, which leveraged a natural experiment created by the transition from live to recombinant shingles vaccines. The study found that recipients of the recombinant vaccine had a significantly lower risk of dementia over six years, with a 17% increase in diagnosis-free time – equivalent to 164 additional days without a dementia diagnosis for those eventually affected. The effect observed across various analyses, was more pronounced in women, and was stronger compared to other vaccines commonly administered to older adults, including influenza and tetanus-diphtheria-pertussis vaccines. The study's authors called for further research into the underlying biological mechanisms and a large-scale randomised controlled trial. In the UK, the recombinant zoster vaccine Shingrix, is offered to all adults turning 65, those aged 70 to 79 years, and those who are 50 years and above with a severely weakened immune system. It is the only US Food and Drug Administration (FDA)-approved shingles vaccine and has dominated the market since its US approval in 2017, outperforming MSD's now-discontinued Zostavax. In 2020, Zostavax was discontinued in the US given Shingrix's better effectiveness and safety. The UK Health Security Agency (UKHSA) announced in September 2023 that all newly eligible individuals would receive Shingrix instead of Zostavax. GSK's vaccine generated £3.36bn ($4.35bn) in sales in 2024, as per the company's financials. According to GlobalData's Pharma Intelligence Center, Shingrix sales will surpass $5bn by 2030. GlobalData is the parent company of Pharmaceutical Technology. "GSK and UK researchers plan to study Shingrix and dementia risk reduction link" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
07-03-2025
- Business
- Yahoo
Jazz Pharmaceuticals bids for Chimerix in $935m deal
Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately $935m in cash. The deal, disclosed on Wednesday 5 March, will see Jazz pay $8.55 per share, representing a 72.4% premium to Chimerix's 4 March closing price of $4.96. Both companies have approved the transaction, which is expected to close in Q2 2025. Chimerix's shares were up 69% when the markets opened, approaching Jazz's offer price. The acquisition will give Jazz access to Chimerix's lead investigational candidate dordaviprone, which is under review by the US Food and Drug Administration (FDA) for the treatment of recurrent H3 K27M-mutant diffuse glioma, a rare and aggressive brain tumour that primarily affects children and young adults. Currently, there are no FDA-approved therapies for this condition, and patients typically face a poor prognosis with limited treatment options beyond radiotherapy and palliative care. The FDA is expected to issue a decision on dordaviprone by 18 August 2025. The drug is also being evaluated in the Phase III ACTION trial (NCT05580562), which has enrolled newly diagnosed patients with non-recurrent H3 K27M-mutant diffuse glioma following radiation treatment. If the trial proves successful, dordaviprone could be used as a front-line therapy. Dordaviprone is designed to activate stress responses in cancer cells, pushing them into apoptosis by acting on the mitochondrial protease ClpP and dopamine receptor D2 (DRD2). According to GlobalData's Pharma Intelligence Center, dordaviprone is forecast to generate up to $385m in global sales by 2030. GlobalData is the parent company of Pharmaceutical Technology. The acquisition of Chimerix follows Jazz's November 2024 FDA approval of Ziihera (zanidatamab), a HER2-directed bispecific antibody for biliary tract cancer. Jazz has also been developing Ziihera for HER2-positive breast and gastric cancers. In 2021, the company acquired GW Pharmaceuticals for $7.2bn, gaining the seizure medication Epidiolex (cannabidiol). In February 2024, it licensed a KRAS inhibitor programme from UK-based Redx Pharma in a deal worth up to $880m. Chimerix originally acquired dordaviprone in 2021 through its purchase of Oncoceutics, in a deal that could be worth over $400m if all milestones are met. If ONC201 receives FDA approval, Chimerix could be eligible for a priority review voucher, a programme designed to incentivise drug development for rare paediatric diseases. In the announcement accompanying the deal, Jazz stated that dordaviprone has patent protection extending to 2037. 'If approved, dordaviprone has the potential to rapidly become a standard of care for a rare oncology disease and also contribute durable revenue beginning in the near-term,' added Jazz's CEO Bruce Cozadd. The acquisition follows a broader trend of significant M&A activity in the pharmaceutical sector since the start of 2025, with major deals from companies such as Johnson & Johnson, Eli Lilly, and GSK, each valued at over $1bn. "Jazz Pharmaceuticals bids for Chimerix in $935m deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
07-03-2025
- Business
- Yahoo
Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talks
Merck KGaA reaffirmed its strong performance in the healthcare sector in its FY 2024 earnings report, but provided little additional information on ongoing acquisition talks with SpringWorks Therapeutics. Speculation surrounding a potential transaction between the two companies first emerged on 10 February 2025, when Reuters reported that Merck KGaA was engaged in discussions to acquire SpringWorks. The same day, Merck KGaA acknowledged the negotiations, but stressed that there was no certainty a deal would be finalised. SpringWorks' stock price surged by 34% following the disclosure of the discussions, pushing its market capitalisation over $4bn. During a 6 March press call, Merck KGaA's CEO Belén Garijo stated that there 'is very little that we can say at this time,' regarding the ongoing talks. A successful acquisition would provide Merck KGaA with SpringWorks' portfolio of targeted oncology therapies, including Ogsiveo (nirogacestat), which is approved for desmoid treating tumours, as well as the MEK inhibitor Gomekli (mirdametinib), which was recently approved in February 2025 for treating neurofibromatosis type 1 (NF1), a rare genetic disorder. According to GlobalData's Pharma Intelligence Center, Gomekli is projected to generate up to $564m in global sales by 2030, while Ogsiveo sales are expected to reach $1.2bn by the same year. GlobalData is the parent company of Pharmaceutical Technology. Garijo emphasised that Merck KGaA's broader merger and acquisition (M&A) strategy remains focused on targeted, lower-risk deals aimed at strengthening its life sciences and healthcare portfolio, particularly through late-stage in-licencing opportunities. 'This is going to be absolutely limited to clear cut, low risk deals that will create value from very early on. So rest assured, we will fully comply with this and stay extremely disciplined when executing our M&A agenda,' said Garijo in a call to investors. The company's healthcare division reported 7% net sales growth in 2024, reaching €8.5bn ($9.2bn). Oncology was a key driver of this performance, with sales in the segment increasing by 12.7% to €2bn ($2.17bn). The company has made moves in the oncology space in recent years, including an October 2024 acquisition of Modifi Biosciences, a Yale University-spinout focused on DNA repair-targeting cancer therapies. Merck KGaA acquired all outstanding shares of Modifi through a subsidiary for an upfront payment of $30m, with the potential for additional milestone payments totalling up to $1.3bn. Merck KGaA's top-selling product in 2024 was Erbitux (cetuximab), which generated €1.16bn ($1.25bn) in revenue. The drug – a monoclonal antibody used in the treatment of certain head and neck cancers as well as colorectal cancer – is expected to see continued sales growth, with GlobalData's projections estimating it could generate $1.9bn in annual revenue by 2030. "Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talks" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
04-03-2025
- Business
- Yahoo
Genentech wins FDA approval for second stroke treatment
Genentech has secured a second marketed stroke therapy after the US Food and Drug Administration (FDA) approved a label expansion for clot-dissolving agent TNKase (tenecteplase) – the first stroke medicine approved by the agency in almost 30 years. TNKase will be available for the treatment of acute ischemic stroke in adults, joining the Roche subsidiary's Activase (alteplase) on the market – also approved for the same indication. Before TNKase, Activase was the only pharmacological treatment approved by the FDA for acute ischemic stroke. Whilst Genentech has enjoyed market domination since 1996 – the year in which Activase was approved – the company pursued TNKase's approval for the disease to offer a faster and simpler administration method. Genentech's new stroke drug is delivered as a single five-second intravenous (IV) bolus, whereas Activase is administered as an IV bolus followed by a one-hour infusion. The differences in administration come down to TNKase's longer half-life and higher fibrin specificity. Genentech said it will also introduce a new 25mg vial configuration in the coming months to support the approval of TNKase in its latest indication. The expanded approval of TNKase was based on a non-inferiority study (NCT03889249) across 22 stroke centres in Canada that demonstrated it performs comparably to Activase in terms of safety and efficacy in acute ischemia patients. Stroke is the fifth leading cause of death in the US, according to the US Centers for Disease Control and Prevention (CDC). More than 795,000 people in the US have a stroke each year, with 87% of those being ischemic stroke. TNKase is one of Genentech's cardiovascular staples, having been approved nearly 25 years ago for the treatment of heart attacks and acute myocardial infarctions. The drug works by breaking down fibrin, a component of blood clots. It is a modified version of a tissue plasminogen activator and helps blood flow freely again without causing systemic bleeding. Combined global sales of TNKase and Activase generated SFr1.2bn ($1.35bn) last year, as per Roche's product sales report. GlobalData's Pharma Intelligence Center expects peak sales to come this year, with future sales potentially impacted by increased competition and shortages. TNKase, under a different brand name in Europe, already experienced a shortage in 2022. GlobalData is the parent company of Pharmaceutical Technology. Boehringer Ingelheim markets Activase and TNKase under the brand names Actilyse and Metalyse, respectively, outside the US, Canada and Japan. "Genentech wins FDA approval for second stroke treatment" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
